Abstract
The dentate gyrus (DG) is one of only two brain structures known to retain the ability to produce new neurons in adulthood. The functional significance of adult neurogenesis in the DG is not yet well understood, but recent evidence has implicated adult neurogenesis in the etiology and treatment of depression. Elevated stress hormone levels, which are present in some depressed patients and can precipitate the onset of depression, reduce neurogenesis in animal models. Conversely, virtually all antidepressant treatments studied to date, including drugs of various classes, electroconvulsive therapy, and behavioral treatments, increase neurogenesis in the DG. We critically review this literature linking DG neurogenesis with depression, looking to both animal and human studies. We conclude that a reduction in neurogenesis by itself is not likely to produce depression. However, at least some therapeutic effects of antidepressant treatments appear to be neurogenesis-dependent. We review the cellular pathways through which antidepressant drugs boost neurogenesis and present several hypotheses about how DG neurogenesis may be instrumental in the therapeutic effects of these drugs.
Keywords: subgranular zone, long-term potentiation, Emotion, Stress, Hippocampal Atrophy
CNS & Neurological Disorders - Drug Targets
Title: Adult Hippocampal Neurogenesis as Target for the Treatment of Depression
Volume: 6 Issue: 3
Author(s): Michael R. Drew and Rene Hen
Affiliation:
Keywords: subgranular zone, long-term potentiation, Emotion, Stress, Hippocampal Atrophy
Abstract: The dentate gyrus (DG) is one of only two brain structures known to retain the ability to produce new neurons in adulthood. The functional significance of adult neurogenesis in the DG is not yet well understood, but recent evidence has implicated adult neurogenesis in the etiology and treatment of depression. Elevated stress hormone levels, which are present in some depressed patients and can precipitate the onset of depression, reduce neurogenesis in animal models. Conversely, virtually all antidepressant treatments studied to date, including drugs of various classes, electroconvulsive therapy, and behavioral treatments, increase neurogenesis in the DG. We critically review this literature linking DG neurogenesis with depression, looking to both animal and human studies. We conclude that a reduction in neurogenesis by itself is not likely to produce depression. However, at least some therapeutic effects of antidepressant treatments appear to be neurogenesis-dependent. We review the cellular pathways through which antidepressant drugs boost neurogenesis and present several hypotheses about how DG neurogenesis may be instrumental in the therapeutic effects of these drugs.
Export Options
About this article
Cite this article as:
Drew R. Michael and Hen Rene, Adult Hippocampal Neurogenesis as Target for the Treatment of Depression, CNS & Neurological Disorders - Drug Targets 2007; 6 (3) . https://dx.doi.org/10.2174/187152707780619353
DOI https://dx.doi.org/10.2174/187152707780619353 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Research on Opioid Receptor Function
Current Drug Targets Review of Treatment for Cocaine Dependence
Current Drug Abuse Reviews (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function
Current Drug Metabolism Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism Current Issues on Epileptic Women
Current Pharmaceutical Design Neuroprotection Against Ischemic / Hypoxic Brain Damage: Blockers of Ionotropic Glutamate Receptor and Voltage Sensitive Calcium Channels
Current Drug Targets The Brain Protective Effect of rTMS (Repetitive Transcranial Magnetic Stimulation) in Depression: A Mini-Review in Animal Studies
Medicinal Chemistry Studies on Target Genes of General Anesthetics
Current Drug Targets Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Analyses of Associations Between Reactive Oxygen Metabolites and Antioxidant Capacity and Related Factors Among Healthy Adolescents
Current Aging Science Traumatic Brain Injury: Preclinical Imaging Diagnostic(s) and Therapeutic Approaches
Current Pharmaceutical Design Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Review of the Biological Activity of Maslinic Acid
Current Drug Targets Molecular Mechanism of a Specific NLRP3 Inhibitor to Alleviate Seizure Severity Induced by Pentylenetetrazole
Current Molecular Pharmacology Pharmacokinetic Studies in Infants Using Minimal-Risk Study Designs
Current Clinical Pharmacology Benzodiazepines and Sleep Architecture: A Systematic Review
CNS & Neurological Disorders - Drug Targets Nanotechnology as Potential Strategy for the Treatment of Pharmacoresistant Epilepsy and Comorbid Psychiatric Disorders
Mini-Reviews in Medicinal Chemistry Current Pharmaceutical Treatments and Alternative Therapies of Parkinson’s Disease
Current Neuropharmacology Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Intraoperative Seizures: Anesthetic and Antiepileptic Drugs
Current Pharmaceutical Design